about
Development of Liposomal Ciprofloxacin to Treat Lung InfectionsCoarse spray delivery to a localized region of the pulmonary airways for gene therapy.Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.Pulmonary formulations: what remains to be done?Liposomal formulations for inhalation.Inhaled antibiotics to treat lung infection.Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug.Comment on: inhaled antimicrobial therapy--barriers to effective treatment, by J. Weers, inhaled antimicrobial therapy - barriers to effective treatment, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013.Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties.Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers.Modifying the release properties of liposomes toward personalized medicine.Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop.Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.Will pulmonary drug delivery for systemic application ever fulfill its rich promise?Formation of drug nanocrystals under nanoconfinement afforded by liposomesCurrent and Emerging Inhaled Therapies of Repositioned DrugsDrug nanocrystallisation within liposomesCorrection: Formation of drug nanocrystals under nanoconfinement afforded by liposomesDevelopment and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for InhalationPersonalizing aerosol medicine: development of delivery systems tailored to the individualInhalation delivery systems with compliance and disease management capabilitiesInvestigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an exampleEquivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop reportEffective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal CiprofloxacinMicrobiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infectionDirect Comparison of Standard Transmission Electron Microscopy and Cryogenic-TEM in Imaging Nanocrystals Inside LiposomesSolid State Characterization of Ciprofloxacin Liposome Nanocrystals
P50
Q26764772-F3E52403-7C23-413E-8570-657BBF58B26CQ30840207-E288E52F-0983-43D5-AF9B-2EA69C9BBF55Q36627996-FF4D8A64-1DB2-4000-8D35-2B4B9CDDEFE8Q37816437-A66F50B6-88BE-4386-8E1A-D6C14C92FE0CQ38126942-AE357234-7EAC-437D-97AF-652ECB86E3ACQ38162996-AE592AAE-2A68-409B-A43E-CC76B9A3322EQ38211140-8D3C9ECD-7784-4EBF-B0A0-15F714F48CCAQ39126354-87EFE0CC-A809-4B53-826F-53E010EEFCD8Q39308123-6E21165F-6F03-474B-9AD9-973C6F1BAE9FQ41210900-2251162C-3DEF-4B73-8A3D-86ADC831B6FAQ41285085-9D5E85FC-A1CD-4C9B-B2F3-61C8DA2FCDA3Q41603902-F5B289A6-519F-4C7A-BEDD-BF360016F268Q41608294-CB25DFDA-EF90-4023-AEA1-DBE6561D9FD8Q45980818-C0806164-C43F-4F64-9B70-96DCDAA30241Q45983241-82FC7DAE-7A23-44BF-A7AB-40567D163775Q46906689-2B447595-E9DB-4EE0-99F2-42A4B0BECBABQ48507010-7CE398F3-DB56-4D6A-88C2-BD449DD16342Q54485756-D04BE2CA-A948-4E7C-90BE-3CE362AE7F2AQ58493073-0AF59FE0-C2C2-4093-8179-97F27EBEAE7AQ58566390-090B125D-29D5-437D-8A08-1430AD4E838CQ59233861-65635FD5-37D2-4E29-B5E0-5F67401C0D48Q59234206-430977F0-4C78-4E19-863A-E7D46703F452Q59291759-85B1E2B1-7119-4DB8-9FD8-0D44856F1F4EQ59291822-F8C5B1CF-9E6B-4AF9-A6DF-E144485AF11FQ77314538-31CA57C0-0423-41FA-AE2A-5162A4EDF3C8Q77974386-3BB7DF5C-551B-4DAC-847E-4EA3FD916946Q83633370-262C4806-010F-47E8-9D01-31EEB303654DQ90254039-B2BBEEE0-6583-4334-8774-C5F70045AE10Q91608251-CE44FD0F-E8B4-4720-921B-CD90BED73D8EQ91955387-34466616-0949-44ED-8AA1-FB0659BEA778Q93363505-2E6B3604-BA93-43CF-969A-C1DCBAA4453D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Cipolla
@ast
David Cipolla
@en
David Cipolla
@es
David Cipolla
@nl
David Cipolla
@sl
type
label
David Cipolla
@ast
David Cipolla
@en
David Cipolla
@es
David Cipolla
@nl
David Cipolla
@sl
prefLabel
David Cipolla
@ast
David Cipolla
@en
David Cipolla
@es
David Cipolla
@nl
David Cipolla
@sl
P106
P1153
6601959262
P21
P31
P496
0000-0002-5773-4721